Patients deserve meaningful savings for the treatments they depend on. That’s why Pfizer and the Ready for Cures community are working to advance smart public policies that reduce patients’ out-of-pocket costs at the pharmacy counter and improve access to treatments — without stifling scientific innovation that could lead to life-saving cures. Potential solutions to accomplish these goals include the following:
Reauthorize the Prescription Drug User Fee Act (PDUFA): While a majority of the FDA’s overall budget comes from the U.S. government, PDUFA requires biopharmaceutical companies, such as Pfizer, to pay user fees that partially support the FDA’s review process for drug evaluation, inspection, and surveillance. The reauthorization of PDUFA later this year is critical to expediting the drug approval process, keeping pace with rapid scientific progress, and ensuring patient access to innovative new therapies. Learn more about PDUFA.
Reject Medicare pricing proposals that could jeopardize the development of crucial medicines, vaccines, and life-saving treatments: Dangerous proposals to implement a government price setting model could undermine Medicare protections that provide beneficiaries robust choice and access to life-saving medicines. This proposal could result in higher medicine costs and fewer drug options under Medicare. Learn more about the dangerous Medicare reform proposal.
Ensure patients receive the savings they deserve: In the current broken rebate system, insurers and pharmacy benefit managers negotiate substantial rebates with pharmaceutical companies to lower the price of medicines. Instead of passing the rebate on to patients, middlemen are siphoning off these savings. And it’s only getting worse: Data reveals that insurers are siphoning off more profits than ever before. Get the facts and learn how to help patients access healthcare savings.
Increase the use of biosimilars: Biosimilars are FDA-approved and often offer a lower-cost alternative to biologic therapies that treat challenging diseases like cancer, diabetes, and rheumatoid arthritis. Biosimilars give patients a safe and often lower cost option than their originator biologics Learn more about biosimilars.
Join the Ready for Cures community to receive updates on how you can help reduce out-of-pocket costs for patients and protect scientific innovation.